Actively Recruiting
Evaluating SCTB35 Plus Lenalidomide Versus Rituximab Plus Lenalidomide in Adults With Relapsed or Refractory Follicular Lymphoma
Led by Sinocelltech Ltd. · Updated on 2026-08-13
93
Participants Needed
1
Research Sites
56 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of SCTB35 combined with lenalidomide in adults with relapsed or refractory follicular lymphoma FL. This Phase 3 randomized trial compares this combination against rituximab plus lenalidomide in patients who have previously received anti-CD20 antibody treatments and urgently need systemic therapy. The study is sponsored by Sinocelltech Ltd. and aims to better understand treatment outcomes for this patient group. Participants will receive either SCTB35 by subcutaneous injection combined with oral lenalidomide or intravenous rituximab plus oral lenalidomide. The trial follows a parallel design where participants are randomly assigned to one of these two treatment groups. Treatments will be administered according to specified doses and schedules, and the study will continue until disease progression or other criteria are met. Throughout the study, participants will be closely monitored for adverse events and progression-free survival over approximately three years. Additional assessments will include measuring overall response rates, complete response rates, overall survival, duration and timing of responses, and blood levels of SCTB35. Safety will also be evaluated through antibody monitoring. Regular visits and evaluations will help researchers gather comprehensive data on treatment effects and participant health during the study period.
CONDITIONS
Brief Title
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here